One of the reasons it is difficult to do that is because these industries have a lot of influence on how policy gets made.
I appreciate that. Just to close, I would say that, within that larger construct, it can be frustrating sometimes.
What worries me is this is all part of a campaign by the GOP and the right wing to work the refs--complaining of non-exi...
But what is really frustrating to me about today's inquiry is that my Republican colleagues know there are plenty of oth...
Thank you, Mr. Chairman. I want to thank the panel for your testimony. Very important pieces of legislation that we are ...
I commend you for that. I have just introduced in the last few days something we are calling the biosimilars competition...
Thank you for your work to implement 21st Century Cures, which obviously as you know is a point of real pride for this c...
Based on the experience with what happened with some of the 21 States last time and the way the alert was given but then...
We need to know in real-time that the alerts are being--that the threats are being taken seriously.
These mergers are kind of out of control. They're putting the consumer, really, in a very, very bad position.
I think there's a study out there that shows that while brand name drugs are about 10 percent of all drugs that are disp...